Transcription of Understanding DARZALEX Interference With Blood ...
{{id}} {{{paragraph}}}
Example: barber
Understanding DARZALEX Interference With Blood ...
Understanding DARZALEX Interference With Blood Compatibility TestingDARZALEX (daratumumab) Results in a False Positive Indirect Coombs Test DARZALEX is a human monoclonal antibody for the treatment of multiple myeloma1 DARZALEX binds to CD38,2 a protein that is expressed on red Blood cells (RBCs)3-5 DARZALEX binding to RBCs interferes with Blood bank compatibility tests, including the antibody screening and crossmatching2 (both indirect Coombs tests) that are part of a routine pretransfusion workupRBCsPatient serumwithout antibodiesto minor antigenNo patient antibodiesto bind RBC antigensCoombsreagentNoagglutinationNega tiveindirectCoombs testRBCsPatient serumcontaining antibodiesto minor antigenPatient antibodiesbind RBC antigensCoombsreagentAgglutinationPositi veindirectCoombs testRBCsPatient serumcontaining DARZALEX DARZALEX binds CD38on RBCsCoombsreagentAgglutinationFalse positiveindirectCoombs testRBCs, red Blood Negative Indirect Coombs TestTypical Positive Indirect Coombs TestTypical Indirect Coombs Test From a DARZALEX -treated PatientHelp Prevent Blood Transfusion Delays Blood compatib
DARZALEX® (daratumumab) Interference Is Clinically Manageable Additional Resources • To date, no clinically significant hemolysis has been observed in patients receiving DARZALEX®, and no transfusion reactions have occurred in patients requiring RBC and whole blood transfusions (data on file)
Loading..
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: